Trial
NCT04163900
Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
NuCana plc
Collaborators
—
Condition
Biliary Tract Cancer
Intervention
NUC-1031
Why stopped
A pre-planned futility analysis concluded that NUC-1031 plus cisplatin was unlikely to achieve its primary objective of improving overall survival. Based on the IDMC's recommendation, NuCana has closed the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-05-24